Poster

Zuranolone Safety and Tolerability in Adults with Postpartum Depression: Analyses from SKYLARK, a 50 mg Placebo-Controlled Study

In the SKYLARK Study, zuranolone 50 mg was generally well tolerated in adults with postpartum depression; treatment-emergent adverse events (TEAEs) led to zuranolone dose reduction and di...

10/26/2023

Unique Features of the Rapid Mood Screener Enable Detection of Bipolar I Disorder in a Primary Care Practice

The Rapid Mood Screener (RMS) is a self-administered screening tool to help differentiate bipolar I disorder from major depressive disorder. Cases were identified from a primary care sett...

10/26/2023

Use Of VMAT2 Inhibitors For Tardive Dyskinesia In Geriatric Populations - A Case Study

This case report discusses the safety and efficacy of VMAT2 inhibitors in treating antipsychotic induced tardive dyskinesia in adults >55 years old. It also highlights the increased ri...

10/26/2023

Using Chess as a Novel Means to Cure Treatment Refractory Catatonia

The subject matter of the poster includes a case report of a patient with treatment refractory catatonia whose condition rapidly improved following a game of chess, one of the patient's k...

10/26/2023

Understanding the Real-World Prescription Patterns and Impact of Atypical Antipsychotic Augmentation Timing on Healthcare Cost in Adult Major Depressive Disorder in the United States: A Systematic Literature Review

This study examined the utilization pattern of augmentation with atypical antipsychotics after partial or no response to antidepressants in patients with MDD. The antidepressant prescript...

10/26/2023

Treatment Patterns From OASIS: Observational Study of Long-Acting Injectables in Schizophrenia

OASIS was a 12-month observational study evaluating real-world outcomes of atypical long-acting injectable (aLAI) antipsychotics in patients with schizophrenia. Most patients initiated aL...

10/26/2023

TV-46000—a Long-Acting Subcutaneous Antipsychotic (LASCA) for the Treatment of Schizophrenia: Local Tolerability and Injection Site Reactions

TV-46000 is a long-acting subcutaneous antipsychotic (LASCA) that combines risperidone and an innovative delivery technology in a suspension suitable for subcutaneous administration in th...

10/26/2023

Understanding Patient Profiles among Medicaid Patients with Treatment-resistant Depression Initiated on Esketamine

Real-world data studies on esketamine use for treatment-resistant depression (TRD) in the US have previously focused on commercially-insured patients. In this study of Medicaid beneficiar...

10/26/2023

Understanding Profiles of Patients with Treatment-resistant Depression by Stringency of Health Plan Prior Authorization Criteria for Approval of Esketamine

In the United States, some health plans have more stringent prior authorization (PA) criteria for esketamine insurance coverage for treatment-resistant depression (TRD), requiring more th...

10/26/2023

Understanding the Experiences of Patients With Major Depressive Disorder Treated With Zuranolone: Qualitative Interviews With Participants From the Open-Label SHORELINE Study

Researchers conducted qualitative interviews to understand patients’ experiences with and perceptions of zuranolone, an oral, investigational, once-daily, 14-day treatment course in clini...

10/26/2023